当前位置: X-MOL 学术J. Alzheimer’s Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration.
Journal of Alzheimer’s Disease ( IF 3.4 ) Pub Date : 2020-08-14 , DOI: 10.3233/jad-200608
Alberto Benussi 1 , Nicholas J Ashton 2, 3, 4, 5 , Thomas K Karikari 2 , Stefano Gazzina 6 , Enrico Premi 7 , Luisa Benussi 8 , Roberta Ghidoni 8 , Juan Lantero Rodriguez 2 , Andreja Emeršič 2, 9 , Giuliano Binetti 10 , Silvia Fostinelli 8 , Marcello Giunta 1 , Roberto Gasparotti 11 , Henrik Zetterberg 2, 9, 12, 13 , Kaj Blennow 2, 9 , Barbara Borroni 1
Affiliation  

Background:It is still unknown if serum glial fibrillary acidic protein (GFAP) is a useful marker in frontotemporal lobar degeneration (FTLD). Objective:To assess the diagnostic and prognostic value of serum GFAP in a large cohort of patients with FTLD. Methods:In this retrospective study, performed on 406 participants, we measured serum GFAP concentration with an ultrasensitive Single molecule array (Simoa) method in patients with FTLD, Alzheimer’s disease (AD), and in cognitively unimpaired elderly controls. We assessed the role of GFAP as marker of disease severity by analyzing the correlation with clinical variables, neurophysiological data, and cross-sectional brain imaging. Moreover, we evaluated the role of serum GFAP as a prognostic marker of disease survival. Results:We observed significantly higher levels of serum GFAP in patients with FTLD syndromes, except progressive supranuclear palsy, compared with healthy controls, but not compared with AD patients. In FTLD, serum GFAP levels correlated with measures of cognitive dysfunction and disease severity, and were associated with indirect measures of GABAergic deficit. Serum GFAP concentration was not a significant predictor of survival. Conclusion:Serum GFAP is increased in FTLD, correlates with cognition and GABAergic deficits, and thus shows promise as a biomarker of disease severity in FTLD.

中文翻译:

血清胶质纤维酸性蛋白 (GFAP) 是额颞叶变性疾病严重程度的标志。

背景:血清胶质纤维酸性蛋白(GFAP)是否是额颞叶变性(FTLD)的有用标志物,目前尚不清楚。目的:评估血清 GFAP 在一大群 FTLD 患者中的诊断和预后价值。方法:在这项对 406 名参与者进行的回顾性研究中,我们使用超灵敏单分子阵列 (Simoa) 方法测量了 FTLD、阿尔茨海默病 (AD) 患者和认知未受损的老年对照患者的血清 GFAP 浓度。我们通过分析与临床变量、神经生理学数据和横断面脑成像的相关性来评估 GFAP 作为疾病严重程度标志物的作用。此外,我们评估了血清 GFAP 作为疾病存活预后标志物的作用。结果:我们观察到 FTLD 综合征患者的血清 GFAP 水平显着高于健康对照,但与 AD 患者相比,进行性核上性麻痹除外。在 FTLD 中,血清 GFAP 水平与认知功能障碍和疾病严重程度的测量相关,并与 GABA 能缺陷的间接测量相关。血清 GFAP 浓度不是生存的重要预测因子。结论:血清 GFAP 在 FTLD 中增加,与认知和 GABA 能缺陷相关,因此有望作为 FTLD 疾病严重程度的生物标志物。并且与 GABAergic 缺陷的间接测量相关。血清 GFAP 浓度不是存活率的重要预测因子。结论:血清 GFAP 在 FTLD 中增加,与认知和 GABA 能缺陷相关,因此有望作为 FTLD 疾病严重程度的生物标志物。并且与 GABAergic 缺陷的间接测量相关。血清 GFAP 浓度不是生存的重要预测因子。结论:血清 GFAP 在 FTLD 中增加,与认知和 GABA 能缺陷相关,因此有望作为 FTLD 疾病严重程度的生物标志物。
更新日期:2020-08-14
down
wechat
bug